The company announced that it is looking to move to Phase II after its ulcerative colitis treatment saw success over placebo.
Researchers have uncovered potentially diagnostic gut microbiome signatures and metabolic pathways associated specifically ...
Ustekinumab-stba, manufactured by Celltrion, is expected to be marketed in the United States in February 2025.
We recently published a list of the Jim Cramer Just Discussed These 13 Stocks. In this article, we are going to take a look ...
Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...
Teva Pharmaceuticals is one of the best performing stocks in the SPDR S&P Pharmaceuticals ETF ( XPH) for 2024 as the stock ...
US affiliate and partner Sanofi (SNY) said Tuesday that a phase 2b study of Teva's investigational duvakitug drug to treat ulcerative colitis and Crohn's disease met its primary endpoints. Ulcerative ...
Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn ...
Teva Pharmaceuticals' shares soared and Sanofi's stock moved higher following positive results from the latest trial of their jointly developed treatment for inflammatory bowel disease.
As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...
We are thrilled to welcome Dr. Feagan to our Clinical Advisory Board,” said JD Finley, Chief Executive Officer of Palisade Bio. “Dr. Feagan’s extensive research experience in CD and UC, along with his ...